Nectar Lifesciences has informed that the Board of Directors of the Company at their meeting held today duly approved and took on record the limited reviewed Unaudited Standalone & Consolidated Financial results for the quarter and nine months ended on December 31, 2019, which are enclosed herewith along with the Limited Review Reports of the Auditors thereon.
The above information is a part of company’s filings submitted to BSE.